Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (Stage BCLC C)

Keyphrases

• Sorafenib 100%
• Advanced Hepatocellular Carcinoma 100%
• BCLC C 100%
• Hepatocellular Carcinoma 33%
• Metastasizing 33%
• Time to Progression 33%
• Local Therapy 33%
• Disease Control Rate 33%
• Advanced Stage 16%
• Disease Stage 16%
• Metastatic Stage 16%
• Metastatic Disease 16%
• Hepatocellular Carcinoma Surveillance 16%
• Median Overall Survival 16%
• Systemic Treatment 16%
• Overall Survival Time 16%
• Transarterial Chemoembolization 16%
• Overall Survival of Patients 16%
• Combined Therapy 16%
• Liver Tumor Burden 16%
• Advanced or Metastatic 16%

Nursing and Health Professions

• Liver Cell Carcinoma 100%
• Sorafenib 100%
• Metastasis 33%
• Overall Survival 33%
• Disease Control 33%
• Local Therapy 33%
• Tumor Volume 16%
• Chemoembolization 16%
• Cancer Diagnosis 16%
• Systemic Therapy 16%
• Survival Time 16%
• Disease 16%
• Liver Tumor 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Liver Cell Carcinoma 100%
• Sorafenib 100%
• Disease 50%
• Overall Survival 33%
• Metastasis 33%
• Systemic Treatment 16%
• Retrospective Study 16%
• Survival Time 16%
• Liver Tumor 16%